Francisco Revilla-Peñaloza1,2, Paul Jay Olsoff-Pagovich3, Jose Ramon Ochoa-Gomez3, Roberto Castaneda-Gaxiola4, Ángel Iván Rubio-Gayosso2, Guillermo Ceballos2, Juan Arcadio Molina-Guarneros5. 1. Anesthesiology Service, American British Cowdray Santa Fe Medical Center, No. 154 Carlos Graef Fernandez Av., Santa Fe, Del. Cuajimalpa, 053333, Mexico City, Mexico. 2. Sección de Estudios de posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, CP 11340, Mexico City, Mexico. 3. Plastic and Reconstructive Surgery, ABC Santa Fe Medical Center, No. 154 Carlos Graef Fernandez Av., Santa Fe, Cuajimalpa, 053333, Mexico City, Mexico. 4. Angiology and Vascular Surgery, ABC Santa Fe Medical Center, No. 154 Carlos Graef Fernandez Av., Santa Fe, Cuajimalpa, 053333, Mexico City, Mexico. 5. Pharmacology Department, Faculty of Medicine, National Autonomous University of Mexico, Av. Universidad No. 3000, Colonia Ciudad Universitaria, CP 04510, Alcaldía Coyoacan, Mexico City, Mexico. jamg@unam.mx.
Abstract
BACKGROUND: Deep vein thrombosis (DVT) is a common complication during postoperative convalescence characterized by hypercoagulability, vascular endothelium damage and blood stasis. It increases noticeably in peri/postoperative phases of surgery procedures. Pulmonary embolism secondary to iliofemoral DVT is a frequent cause of death. METHODS: Adult patients scheduled for plastic and reconstructive surgery (PRSx) with moderate to high thrombogenic risk were selected. We evaluated the efficacy and safety of bemiparin compared to enoxaparin as chemoprophylaxis for DVT. Following balanced general anesthesia techniques, patients were randomly assigned for subcutaneous enoxaparin 40 IU (Group-E) or bemiparin 3500 IU (Group-B) q24h starting 6 h after procedure conclusion for at least 10 days. All patients were evaluated for DVT through Doppler ultrasound mapping of the lower limbs. RESULTS: Seventy-eight patients were evaluated, mostly women (83%), physical status ASA II (59%), ASA III (10%); Caprini's thrombogenic risk score 3-4 (moderate) 58%, 5-6 (high) 29%, > 6 (too high) 13%; demographics, clinical variables and scores were similar between groups. Median drainage time in breast surgery was 4 days in both groups (p = 0.238). In the case of abdominal surgery, median was 14 days in Group-E versus 13 days in Group-B (p = 0.059). No DVT was detected in either group. CONCLUSIONS: DVT was prevented with bemiparin, without significant bleeding increase nor adverse events; moreover, the cost of bemiparin is lower than enoxaparin. Bemiparin can be considered as alternative drug for DVT chemoprophylaxis in PRSx procedures. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
BACKGROUND: Deep vein thrombosis (DVT) is a common complication during postoperative convalescence characterized by hypercoagulability, vascular endothelium damage and blood stasis. It increases noticeably in peri/postoperative phases of surgery procedures. Pulmonary embolism secondary to iliofemoral DVT is a frequent cause of death. METHODS: Adult patients scheduled for plastic and reconstructive surgery (PRSx) with moderate to high thrombogenic risk were selected. We evaluated the efficacy and safety of bemiparin compared to enoxaparin as chemoprophylaxis for DVT. Following balanced general anesthesia techniques, patients were randomly assigned for subcutaneous enoxaparin 40 IU (Group-E) or bemiparin 3500 IU (Group-B) q24h starting 6 h after procedure conclusion for at least 10 days. All patients were evaluated for DVT through Doppler ultrasound mapping of the lower limbs. RESULTS: Seventy-eight patients were evaluated, mostly women (83%), physical status ASA II (59%), ASA III (10%); Caprini's thrombogenic risk score 3-4 (moderate) 58%, 5-6 (high) 29%, > 6 (too high) 13%; demographics, clinical variables and scores were similar between groups. Median drainage time in breast surgery was 4 days in both groups (p = 0.238). In the case of abdominal surgery, median was 14 days in Group-E versus 13 days in Group-B (p = 0.059). No DVT was detected in either group. CONCLUSIONS: DVT was prevented with bemiparin, without significant bleeding increase nor adverse events; moreover, the cost of bemiparin is lower than enoxaparin. Bemiparin can be considered as alternative drug for DVT chemoprophylaxis in PRSx procedures. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Entities:
Keywords:
Bemiparin; Chemoprophylaxis; Deep venous thrombosis; Enoxaparin; Plastic surgery
Authors: Christopher J Pannucci; Steven H Bailey; George Dreszer; Christine Fisher Wachtman; Justin W Zumsteg; Reda M Jaber; Jennifer B Hamill; Keith M Hume; J Peter Rubin; Peter C Neligan; Loree K Kalliainen; Ronald E Hoxworth; Andrea L Pusic; Edwin G Wilkins Journal: J Am Coll Surg Date: 2010-11-18 Impact factor: 6.113
Authors: Alexander T Cohen; Giancarlo Agnelli; Frederick A Anderson; Juan I Arcelus; David Bergqvist; Josef G Brecht; Ian A Greer; John A Heit; Julia L Hutchinson; Ajay K Kakkar; Dominique Mottier; Emmanuel Oger; Meyer-Michel Samama; Michael Spannagl Journal: Thromb Haemost Date: 2007-10 Impact factor: 5.249